Comparison of Therapix Biosciences Ltd. (TRPX) and Benitec Biopharma Limited (NASDAQ:BNTC)

Therapix Biosciences Ltd. (NASDAQ:TRPX) and Benitec Biopharma Limited (NASDAQ:BNTC) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Therapix Biosciences Ltd. 3 0.00 N/A -2.57 0.00
Benitec Biopharma Limited 1 0.00 N/A -0.82 0.00

Table 1 demonstrates Therapix Biosciences Ltd. and Benitec Biopharma Limited’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Therapix Biosciences Ltd. and Benitec Biopharma Limited.

Net Margins Return on Equity Return on Assets
Therapix Biosciences Ltd. 0.00% 0% 0%
Benitec Biopharma Limited 0.00% 0% 0%

Insider and Institutional Ownership

The shares of both Therapix Biosciences Ltd. and Benitec Biopharma Limited are owned by institutional investors at 0% and 4.11% respectively. 2.08% are Therapix Biosciences Ltd.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Therapix Biosciences Ltd. -12.16% 4.84% -24.2% -28.77% -30.48% -20%
Benitec Biopharma Limited 26.87% 11.45% -51.43% -39.29% -60.83% -43.33%

For the past year Therapix Biosciences Ltd.’s stock price has smaller decline than Benitec Biopharma Limited.

Summary

On 2 of the 3 factors Therapix Biosciences Ltd. beats Benitec Biopharma Limited.

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Tel Aviv, Israel.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.